The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights.
The report indicates that this market is entering a new phase of growth propelled by the increasing prevalence of malignant brain tumors, such as glioblastoma, in addition to a remarkable increase in investments in the neuro-oncology field. Many cutting-edge interventions are being integrated in the way patients are treated. These include tumor-treating fields and gene therapy. As a result, patients are increasingly hopeful that a brain tumor diagnosis doesn’t mean their days are numbered.
Traditionally, brain tumors have been managed using surgery followed by radiation therapy. However, the aggressive nature of these tumors meant that these treatments had less than satisfactory efficacy. Now a paradigm shift in the way patients are treated is happening and precision therapies as well as chemotherapy protocols now exist to treat brain cancers.
Early detection of these tumors is also improving with the use of AI-assisted diagnostic systems, according to the report. AI is also helping during drug discovery and development, and these two improvements are helping to advance the ability of treatment teams to detect tumors early and intervene decisively in ways that weren’t possible in the past.
Despite these advancements, the report points out that brain tumor treatment still has major hurdles to navigate, such as the restrictions resulting from the blood-brain barrier, the high cost of these advanced therapies, and the inconsistent effectiveness being observed when these novel treatments are administered to different patients.
The authors of the report indicate that the U.S., China, India, Germany and Brazil are notable leaders in driving the growth of this market. Several factors within these countries are fueling this growth, including the increasing cases of brain malignancies, regulatory support to efforts aimed at developing new treatments, aging populations that face a higher disease burden, expanding research collaborations that are resulting in more clinical trials being conducted, and the increasing access to disposable income that can be used to access these new treatments.
As the market grows at the projected 7.2% CAGR over the next 10 years, companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are well positioned to benefit from this market expansion as their pipelines gradually yield approved treatments indicated for central nervous system malignancies.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
